2 results
6-K
EX-99.1
GLPG
Galapagos NV
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
of epidemiological studies. Rheumatol. Oxf. Engl., 56(11), 1945–1961.
2 González, L. A. et al (2013). Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. Lupus, 22(12), 1214–1224.
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
, and a collaborative mindset. Reduced inequalities We aim to develop a balanced workforce across a number of criteria, including gender, nationality, ethnicity
- Prev
- 1
- Next